IVDR classification of in-vitro diagnostic medical devices: a brief guide for manufacturers
IVDR classification of in-vitro diagnostic medical devices: a brief guide for manufacturers
Regulatory Affairs Medical Devices EU IVDR
Tuesday, 28 September 2021
Wout Vertenten & Ward Neefs, Pharmaceutical Consultants at QbD Group
Share
\
\
X (Twitter) 
\
\
LinkedIn 
\
\
WhatsApp 
\
\
Copy link 
\
\
Mail
Learn more about the new risk-based approach to in-vitro diagnostic device classification under IVDR 2017/746, replacing outdated directives.
IVDR classification of in-vitro diagnostic medical devices: a brief guide for manufacturers | QbD Group
5:46
In vitro diagnostic medical devices (IVDs) have long been a part of our healthcare industry. Recently, however, the use of IVDs has increased drastically. Just think of all SARS-CoV2 diagnostic tests that have been performed over the last 2 years.
Keeping in mind the rapid spread of the coronavirus and its implications, it is easy to see how false-negative test results can have catastrophic consequences. As a result, it is of great importance that these diagnostic tests are reliable.
For many other IVDs, the consequences of incorrect results are equally threatening. Therefore, it is essential that IVDs are regulated in order to ensure public and patient safety. However, since the formal definition of IVDs (see below) spans such a broad range, it is illogical to impose the same regulations on all.
Consequently, a subdivision into four different classes was introduced. This article will thoroughly demonstrate how IVDs are classified according to IVDR, since this classification is the manufacturers’ responsibility.
| ## IVD definition and IVDR classification ### What are ‘in vitro diagnostic medical devices’ or IVDs? “ In-vitro diagnostic medical device” means ‘any medical device which is a reagent, reagent product, calibrator, control material, kit, instrument, apparatus, piece of equipment, software or system, whether used alone or in combination, intended by the manufacturer to be used in vitro for the examination of specimens, including blood and tissue donations, derived from the human body, solely or principally for the purpose of providing information on one or more of the following: - (a) concerning a physiological or pathological process or state, - (b) concerning congenital physical or mental impairments, - (c) concerning the predisposition to a medical condition or a disease, - (d) to determine the safety and compatibility with potential recipients, - (e) to predict treatment response or reactions - or (f) to define or monitor therapeutic measures.’ |
IVDD to IVDR: what, when, and why?
It was only in May 2017 that IVDs were first subjected to uniform European regulations, IVDR 2017/746. These regulations were introduced as an extension of the prior IVD directives (IVDD 98/79/EC), so compared to IVDD no requirements were removed, but additional ones were introduced.
European officials allowed a five-year transition period for manufacturers to adapt their modes of operation to the new IVDR requirements, hence, the IVDR will come into effect on May 26th of 2022.
While IVDD only imposed objectives that were subsequently transposed into national legislation, the IVDR regulations directly have binding legal force in all European member states, thus ensuring uniformity across Europe. Be aware, however, that member states can still impose further restrictions to certain IVDs on top of the European regulations.
Risk-based IVDR classification
The strictness of the IVDR regulations imposed on a specific IVD is completely dependent on its assigned risk-class. Under the IVDD, only IVDs mentioned in two extensive lists were classified in the top two risk classes.
The remaining IVDs were then divided into either the ‘self-test’ category or ‘IVD others’ category. Under IVDR they are now classified in categories from A (low risk) to D (highest risk), based on a set of rules stated in Annex VIII of the IVDR. These rules are further explained in this European guidance document.
The figure below illustrates the list-based approach under IVDD in contrast to the risk-based IVDR classification procedure of IVDs.
Figure 1 – Flowcharts describing the classification process under IVDD and IVDR.
According to the list-based approach used by the IVDD, most of the IVDs were put into the lowest risk class (‘IVD others’) which does not require the approval or involvement of a notified body. The more extensive IVDR classification procedure categorizes a significantly larger fraction of all IVDs in elevated risk classes.
These higher-risk classes are also subject to the approval of notified bodies. Figure 3 illustrates this shift of products from classes of low risk, not requiring approval, to classes of higher risk which do require approval of a notified body. Hence, for many IVDs the stringency of the requirements increases notably compared to before the introduction of the IVDR.
Figure 2 – Comparison between classification proportions under IVDD vs IVDR. [ Source]
To put this into perspective, we can take a look at the example of SARS-CoV2 diagnostic tests and it becomes clear how much effect this new IVDR classification can have. Under IVDD, these tests would fall under the lowest risk class, while they are classified in class D, the highest risk class, under IVDR. Consequently, the manufacturing of SARS-CoV2 tests requires among others notified body approval and individual batches to be tested by a reference laboratory.
IVDR deadline approaching: what now?
The new IVDR brings uniformity to the regulation of the broad range of IVDs, ensuring the safety of patients and the general public across all of Europe.
Thanks to the introduction of a more complete rule-based IVDR classification system approximately 84% of IVDs will now need to be approved by a notified body, compared to less than 7% before.
The implementation of the IVDR has resulted in the need for reclassification as well as certification or recertification for many IVDs.
Still unsure on how to proceed? Our experts are happy to assist you in the transition from IVDD to IVDR. Do not hesitate tocontact us .
Stay ahead in life sciences
Keeping up with the fast-paced life sciences industry doesn’t have to be overwhelming.
Our newsletter delivers the latest insights, industry updates, and expert content directly to your inbox, helping you stay informed and make smarter decisions.
Discover more expert content
Webinar
From Strategy to First-in-Human: A Practical Roadmap for Biotech Development
Join our webinar to learn how to navigate nitrosamine risks and streamline your biotech development from early planning to first-in-human trials. Register now for expert insights.
Webinar
PMS & PMCF Compliance for Medical Devices Under EU MDR
Gain practical insights on PMS & PMCF compliance for medical devices under EU MDR. Watch our webinars on demand.
Case study
A Decade of Excellence: Linguistic Review Support for a Global Pharma Leader
QbD Group streamlines linguistic reviews for a leading pharma client, ensuring compliance and accuracy across 25 EU/EEA languages while meeting stringent regulatory deadlines.
Case study
Supporting Market Access to Essential Medicines in Europe
Support your entry into the European pharmaceutical market with expert regulatory guidance, ensuring compliance and access to essential medicines for patients. Contact us today for assistance.
%20Checklist.jpg)
Whitepaper
Medical Device Regulation (MDR) Checklist
Implement the Medical Device Regulation (MDR) with ease. Download our checklist of mandatory documents for MDR compliance.
Whitepaper
Regulatory Affairs for Pharma and Biotech
In this flyer, you will learn more about the regulatory services QbD Group provides for the pharmaceutical and biotechnology industries.
Whitepaper
Clinical Evaluation for Medical Devices under MDR
This whitepaper will guide you through crucial regulatory documents pertaining to the clinical evaluation process of your medical device. Download now!
Whitepaper
IVDR extension: what does this mean for you?
In this whitepaper, you will learn the impact of the IVDR transition extension and receive tips and strategies to navigate these regulatory changes.
Webinar
Drug-Device Combination Products and Article 117
Explore the regulatory complexities of Drug-Device Combination Products. Learn about Article 117 requirements, Notified Body Opinions, and more.
Whitepaper
Mobile health on the rise: exploring the regulatory landscape for reimbursement
This whitepaper will help you navigate the maze of the DTx regulatory environment, highlighting several important countries and regulations.
Whitepaper
Clinical investigations under MDR: key insights and practical experiences
This whitepaper covers clinical investigation authorization under MDR, the EU Legal Representative's role, and the MDR's impact on study conduct and post-market surveillance.
Case study
CE Mark Renewal for bioXtra Products: A Success Story
Discover how Lifestream Pharma successfully renewed the CE mark for their BioXtra Dry Mouth products under the EU MDR. Learn about the challenges faced, the approach taken for compliance, and the results achieved.
Webinar
Technical Documentation Essentials for Medical Device Software
Gain practical insights on crafting MDR-compliant technical documentation for Medical Device Software.
.jpg)
Webinar
Getting Started: Overcoming Initial Obstacles in Medical Device Software Development
Watch our webinar on demand and learn about regulatory obstacles, MDR, AI Act, and best practices for medical device software development and market entry.
Webinar
Mastering Clinical Performance Studies under IVDR
In the evolving regulatory landscape of IVDs, demonstrating clinical performance is more crucial and challenging than ever. Discover more in this webinar on demand.
Whitepaper
Clinical evidence for In Vitro Diagnostics under IVDR
In this whitepaper, we will guide you through the documents required for the demonstration of clinical evidence under the IVDR. Download now.
Webinar
Post-Market Surveillance Requirements for Medical Devices and IVDs
Learn about post-market surveillance requirements under MDR and IVDR regulations. Gain insights from industry experts in this on-demand webinar.
Whitepaper
The key role of Regulatory Affairs in the pharmaceutical industry: from drug development to commercialization
Discover the key role of Regulatory Affairs in pharma and how Regulatory Affairs teams support product lifecycle management in this whitepaper. Download now.
.jpg)
Webinar
3D Printing in the Healthcare World
Explore the challenges and opportunities of 3D printing in healthcare, featuring expert insights on regulations, pitfalls, and efficiency.
.jpg)
Webinar
IVDR Extension Explained: Tips & Strategies
Gain valuable insights on the IVDR extension and its impact on IVD manufacturers with our webinar on demand.
Whitepaper
Innovations in ATMP: state of the industry in 2024
This whitepaper explores the innovations in ATMP and solutions in detail, with a focus on the current landscape as of April 2024. Download now.
.jpg)
Case study
The journey toward IVDR compliance for the LVOne device
QbD Group helped Upfront Diagnostics gain entry into the MD/IVD industry by supporting them on their path to ISO 13485 certification.
Case study
Ensuring a smooth MDR transition for Oystershell's medical devices
The landscape of medical device regulations is constantly evolving, making it a challenge for companies to keep up. Our collaboration with Oystershell, which began in July 2023, highlights our expertise in transforming complex challenges into success stories, all with a touch of QbD Clinical magic.
Case study
Successful clinical evaluation supports rapid CE marking of Minze Health's Uroflowmeter
QbD Clinical assisted Minze Health, a urology-focused medical devices company, in obtaining CE marking under MDR through clinical evaluation.
.jpg)
Webinar
The Medical Device CE Certification Pathway Explained: From Classification to Conformity Assessment by the Notified Body
Learn about the Medical Device CE Certification Pathway, from classification to conformity assessment by a Notified Body. Join our webinar on demand.
.jpg)
Case study
Helping Relu to comply with changing regulations
QbD Group supported software company Relu with their expertise to comply with changing regulations.
.png)
Case study
Quickly bringing a new COVID-19 medical device to market
Obtaining the required government certifications for a medical device is always a challenge. Especially when the COVID clock is ticking.
Twitter Widget Iframe